ETON - Eton Pharmaceuticals, Inc.
| Previous Close | 6.87 |
| Open | 6.90 |
| Bid | 5.61 x 1300 |
| Ask | 6.86 x 1000 |
| Day's Range | 6.64 - 7.20 |
| 52 Week Range | 5.13 - 10.20 |
| Volume | 139,301 |
| Avg. Volume | 76,871 |
| Market Cap | 121.144M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.07 |
| Earnings Date | Oct 9, 2019 - Oct 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.50 |
- Zacks
Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know
Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- GlobeNewswire
Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference
DEER PARK, Ill., Sept. 03, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
- Zacks
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
- Business Wire
Eton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104
Eton Pharmaceuticals, Inc. (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products today announced positive results from bioequivalence studies of ET-104, Eton’s proprietary oral liquid formulation of a molecule frequently used to treat a severe neurological condition. In bioequivalence studies conducted in 35 human subjects under both fed and fasting conditions, ET-104 demonstrated pharmacokinetic equivalence to a currently FDA-approved oral solid product of the same active ingredient. Based on these successful trial results, Eton anticipates submitting an NDA with the U.S Food and Drug Administration (FDA) for the product in the fourth quarter of 2019.
- Zacks
Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
- Zacks
Regeneron Ebola Treatment Shows Promise, Study Stopped Early
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
- Zacks
Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
- Zacks
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View
Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.
- GlobeNewswire
Eton Announces Second Quarter Financial Results and Highlights Business Progress
ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019 ET-105 Acquisition Closed & Application Assigned PDUFA Date of March 17, 2020Company to Host.
- Zacks
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
- GlobeNewswire
Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
NASHVILLE, Tenn., Aug. 02, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an.
- GlobeNewswire
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105
Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Aucta Pharmaceuticals' New Drug Application for ET-105, an innovative formulation of lamotrigine which Eton acquired the U.S. marketing rights to in June 2019, has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020.
- GlobeNewswire
Eton Pharmaceuticals to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
DEER PARK, Ill., July 30, 2019 -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
- GlobeNewswire
Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019
Harrow Health, Inc. (HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019. The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers. To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here. A dial in replay of the call will be available until September 14, 2019. To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 51861. The webcast replay will be available until November 14, 2019.
- Zacks
Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.
- Benzinga
Eton Pharmaceuticals Shares Slammed After FDA Complete Response Letter
Eton Pharmaceuticals (NASDAQ: ETON ) shares are trading lower after the U.S Food and Drug Administration sent a Complete Response Letter to the company for EM-100. The news first hit wires after Friday's ...
- GlobeNewswire
Eton Pharmaceuticals Provides Update on EM-100 Program
Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S Food and Drug Administration (FDA) provided Eton’s partner with a Complete Response Letter relating to the application for EM-100. “We believe the issues cited in the CRL can be addressed in the coming months, and we remain confident that EM-100 will be available to patients as quickly as possible,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals.
- Simply Wall St.
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) can tell us which group is most powerful...
- American City Business Journals
The city's newest public company wants to build a new industry in Nashville
“If we can bring the right people and the right brains and build out the infrastructure, we think we can build the industry,” Harrow Health CEO Mark Baum said.
- American City Business Journals
Publicly traded San Diego firm moving HQ to Nashville
A publicly traded health care company is relocating from the West Coast to Nashville — but it won’t be the typical Middle Tennessee health care firm.
- Benzinga
The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
- GlobeNewswire
Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update
Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the Company has entered into an agreement with Aucta Pharmaceuticals, Inc to acquire U.S. marketing rights for ET-105. Aucta submitted the product’s New Drug Application (NDA) to the FDA in May 2019 and is seeking approval as an epilepsy treatment to be used as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.
- Simply Wall St.
How Many Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Did Insiders Buy, In The Last Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- GlobeNewswire
Eton Pharmaceuticals to Present at 20th Annual B. Riley FBR Investor Conference
DEER PARK, Ill., May 15, 2019 -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.
